tiprankstipranks
Trending News
More News >

Holding_SuperHero - New Portfolio

David He

Holding_SuperHero
Individual Investor
Ranked #417,189 out of 796,840 TipRanks' Investors
Success Rate
31%
73 out of 236
profitable transactions
Average Return
-9.55%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▼ 8.82%
6-Month Return▼ 7.95%
12-Month Return-
YTD Return▼ 9.94%
Total Return▲ 3.03%

Best Trade

Opened at
Closed at-
Gain▲ 165.52%

Bio

Started Feb 2024

Performance

25.98%0-25.98%
▲ 2.92%
▲ 2.10%
▲ 10.09%
Sep 2024
▲ 10.00%
▼ 0.89%
▼ 1.30%
Oct 2024
▲ 25.98%
▲ 5.96%
▲ 10.41%
Nov 2024
▲ 5.36%
▼ 2.41%
▼ 3.98%
Dec 2024
▲ 6.01%
▲ 2.69%
▲ 4.57%
Jan 2025
▼ 12.86%
▼ 1.27%
▼ 5.08%
Feb 2025
▼ 1.80%
▼ 5.57%
▼ 8.45%
Mar 2025
▼ 3.93%
▼ 5.75%
▼ 0.90%
Apr 2025
TipRanks AverageS&P 500Investor Portfolio
▲ 2.92%▲ 2.10%▲ 10.09%
▲ 10.00%▼ 0.89%▼ 1.30%
▲ 25.98%▲ 5.96%▲ 10.41%
▲ 5.36%▼ 2.41%▼ 3.98%
▲ 6.01%▲ 2.69%▲ 4.57%
▼ 12.86%▼ 1.27%▼ 5.08%
▼ 1.80%▼ 5.57%▼ 8.45%
▼ 3.93%▼ 5.75%▼ 0.90%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Nvidia
18.66%
▼ 16.22%
12
Sell
Apr 16, 2025
MoneyLion
▲ 75.05%
7
Close
Apr 16, 2025
GoodYear Tire
2.16%
▲ 10.88%
1
Open
Apr 16, 2025
YieldMax COIN Option Income Strategy ETF
16.75%
▼ 32.14%
4
Sell
Mar 26, 2025
Capital One Financial
12.11%
▼ 0.37%
2
Buy
Mar 26, 2025
YieldMax SNOW Option Income Strategy ETF
1.91%
▼ 7.65%
2
Buy
Mar 26, 2025
EVgo
2.11%
▼ 47.21%
5
Buy
Mar 20, 2025
Summit Therapeutics
0%
▲ 74.07%
2
Sell
Mar 20, 2025
SoFi Technologies
0%
▼ 21.79%
2
Sell
Mar 06, 2025
YieldMax MSTR Option Income Strategy ETF
19.99%
▲ 14.70%
1
Open
Mar 06, 2025
Strategy
0.09%
▲ 47.66%
14
Sell
Feb 08, 2025
ProShares Ultra Bloomberg Natural Gas
0%
▼ 33.34%
8
Sell
Feb 08, 2025
Meta Platforms
0%
▼ 3.00%
3
Sell
Feb 08, 2025
Permian Resources
0%
▼ 13.25%
2
Sell
Feb 08, 2025
aTyr Pharma
25.58%
▲ 16.35%
8
Sell
Feb 08, 2025
AngioDynamics
0%
▲ 13.66%
3
Sell
Feb 08, 2025
Carnival
0%
▼ 27.10%
2
Sell
Feb 08, 2025
Intel
0%
▼ 1.15%
2
Sell
Feb 08, 2025
Sagimet Biosciences, Inc. Class A
0%
▼ 51.57%
2
Sell
Feb 08, 2025
Y-Mabs Therapeutics
0%
▼ 58.47%
2
Sell
Feb 08, 2025